All articles by Robert Barrie

Robert Barrie

Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob

Vaccine void means current Ebola outbreak declared international emergency

The World Health Organization (WHO) has declared an outbreak of Ebola disease in Sub-Saharan Africa as a public health emergency…
Biopharma industry endorses Pazdur for FDA commissioner role

With the leadership role of the US Food and Drug Administration (FDA) vacant following Marty Makary’s resignation earlier this week,…
Imfinzi set to become first immunotherapy for stomach cancer patients on NHS

AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form…
EU advances plans to reduce reliance on drug imports

The European Union (EU) has taken a major step towards ushering in new rules that will safeguard the supply of…
FDA weighs drug repurposing pathway for underserved diseases

The US Food and Drug Administration (FDA) is considering a new framework that could allow approved medicines to be repurposed…

Cellular Intelligence licenses Novo’s shelved Parkinson’s cell therapy programme

Cellular Intelligence has licensed Novo Nordisk’s cell therapy programme for Parkinson’s disease, seven months after the Danish drugmaker wound down…
Novo’s CEO champions “record-breaking start” for Wegovy pill in US market

Novo Nordisk has had a difficult year, faced with intense competition in the obesity space; however, the company’s Wegovy pill…
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset

Madrigal Pharmaceuticals has gained the global rights to Arrowhead Pharmaceuticals’ small interfering RNA (siRNA) asset for the treatment of metabolic…
Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening

Buoyed by yet another strong quarter fuelled by obesity drug demand, Eli Lilly has raised its sales expectations for the…
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout

Chiesi has conducted the largest acquisition in its 90-year history, agreeing to buy KalVista Pharmaceuticals in a deal worth around…